Clinical Trial

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

Study acronym: MUIR-3
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2024-03-29; most recent amendment 2026-06-24.
Status change: Recruiting → Active, Not Recruiting 2025-07-07
Status change: Not Yet Recruiting → Recruiting 2024-04-27
Trial Details
NCT Number NCT06347133
Lead Sponsor Arrowhead Pharmaceuticals
Conditions Hypertriglyceridemia
Enrollment 1,456 participants
Start Date 2024-05-21
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2026-06-26